Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia.

Details

Serval ID
serval:BIB_99A8CA7D638A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia.
Journal
Archives of Pathology and Laboratory Medicine
Author(s)
Mhawech-Fauceglia P., Oberholzer M., Aschenafi S., Baur A., Kurrer M., Von Rohr A., Hsu-Schmitz S.F., Wagner B., Delacretaz F., Hurwitz N.
ISSN
1543-2165[electronic]
Publication state
Published
Issued date
2006
Volume
130
Number
3
Pages
374-377
Language
english
Abstract
CONTEXT: Minimal residual disease (MRD) in patients treated for hairy cell (HC) leukemia as assessed by immunohistochemistry has not been included routinely in evaluation of treatment results. OBJECTIVE: To assess the presence of persistent HCs after treatment, as detected by immunohistochemistry, and to evaluate the correlation between the level of MRD and clinical outcome. DESIGN: Percentages of DBA.44-positive HCs were assessed on 116 biopsy specimens from 17 patients. The patients had a median follow-up of 55.4 months. RESULTS: Minimal residual disease was seen in 3 patterns. Group 1 (7 patients) had MRD levels ranging from "rare scattered suspicious HCs" to less than 1%. The MRD levels were stable throughout follow-up, and all patients remained in complete remission. Group 2 (6 patients) had MRD levels ranging from 1% to 5%, and 3 patients were in complete remission at 77.9, 63.8, and 108.0 months. Another patient showed evidence of disease activity (partial remission) at 47.6 months. Two other patients relapsed at 12.3 months and at 25.7 months, respectively, with greater than 1% HCs. Group 3 (4 patients) had MRD levels greater than 5%. Three patients relapsed at 11.3, 12.1, and 29.6 months, respectively, with greater than 5% HCs. The fourth patient had MRD levels of 5% at 14.6 months and 2% at 20.0 months but was subsequently lost to follow-up. CONCLUSIONS: Quantitative assessment of MRD may be of value in identifying patients at risk for relapse of hairy cell leukemia.
Keywords
Antineoplastic Agents, Biopsy, Bone Marrow Cells, Cladribine, Follow-Up Studies, Humans, Immunohistochemistry, Injections, Subcutaneous, Leukemia, Hairy Cell, Neoplasm, Residual, Predictive Value of Tests, Remission Induction, Retrospective Studies, Tumor Markers, Biological
Pubmed
Web of science
Create date
29/01/2008 18:35
Last modification date
20/08/2019 15:01
Usage data